TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

NCT ID: NCT00980538

Last Updated: 2025-11-13

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE3
• Total Enrollment: 180 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-12-09
• Study Completion Date: 2032-01-01

Brief Summary

The purpose of this study is to provide etravirine (ETR) through this trial until participants can be switched to locally available ETR-based treatment regimens (that is, commercially available and reimbursed, or accessible through another source [example, access program or government program]), or local standard of care, as appropriate.

Detailed Description

This is open label continued access trial for HIV-1 infected children/adolescents who have completed treatment in clinical (parent) trial with etravirine (ETR) sponsored by/in collaboration with Janssen Research & Development and who continue to benefit from use of ETR. At baseline visit, eligibility criteria will be checked. If eligibility criteria are met, participants will either continue on ETR dose they received in previous ETR (parent) trial or on adjusted dose if required by investigator.ETR dose adjustment will be based on weight using dosing guidelines. Assessment visits are recommended every 3 months (pediatric) and 6 months (adults). For most of participant, their next visit will be final visit with data collection. New participants entering study, will have baseline visit without data collection. Thereafter visits and assessments will be performed per local standard of care and documented in the participant's medical records only. Investigators will continue to report SAEs possibly related to ETR and pregnancies to sponsor using regular reporting. Treatment will be continued until: investigator determines that participant no longer benefits from ETR treatment (e.g based on viral load); treatment limiting toxicity; loss to follow-up; consent withdrawal; pregnancy; program termination by Sponsor; ETR-based treatment regimen becomes commercially available for participant's use, and is reimbursed, or accessed by another source (e.g access/government program) in region participant is living, or participants switched to local standard of care, as appropriate. Adult participants will receive ETR 200mg BID.Pediatric participants will receive ETR, doses as received in previous ETR(parent) trial, with weight based dose adjustment if necessary.

10 to <20kg:100mg BID (4*25mg or 1 tablet 100mg) 20 to <25kg:125mg BID (5*25mg or 1 tablet 100mg+1 tablet 25mg) 25 to <30kg:150mg BID (6*25mg or 1 tablet 100mg+2 tablets 25mg) >= 30kg:200mg BID (8*25mg or 2*100mg)

Conditions

HIV Infections; HIV-1

Keywords

TMC125-TiDP35-C239; TMC125-C239; TMC125; HIV; Etravirine; Intelence; IntelenceTM

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Etravirine

Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.

Group Type: EXPERIMENTAL

Etravirine

Intervention Type: DRUG

Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.

Interventions

Etravirine

Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participants who meet all of the following criteria are eligible for this trial: Documented HIV-1 infection
• Male or female participants, aged 2 years and older
• Successfully completed a clinical (parent) pediatric trial with ETR sponsored by or in collaboration with Janssen Research & Development, and continues to receive benefit from the use of ETR
• Participant (where appropriate, depending on age) and their parent(s) or legal representative(s) have signed the Informed Consent Form (ICF)/Assent voluntarily
• Children will be informed about the program and asked to give assent (where appropriate, depending on age)
• Negative urine pregnancy test for females of childbearing potential

Exclusion Criteria

• Participants meeting one or more of the following criteria cannot be selected: Any condition (including but not limited to alcohol and drug use), which in the opinion of the investigator could compromise the participant's safety or adherence to treatment with ETR
• Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or findings of medical history, laboratory or physical examination that, in the investigator's opinion, would compromise the participant's safety during treatment with ETR
• Previously demonstrated clinically significant allergy or hypersensitivity to ETR or to any of the excipients of ETR
• Pregnant or breastfeeding
• Non-vasectomized heterosexually active boys not using safe and effective birth control methods, or not willing to continue practicing these birth control methods, during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication)
• Girls, who are sexually active and able to become pregnant, not using safe and effective birth control methods, or not willing to continue practicing these birth control methods, during the trial and until 30 days after the end of the trial (or after the last intake of the investigational medication)

• Minimum Eligible Age: 2 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Sciences Ireland UC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Janssen Sciences Ireland UC Clinical Trial

Role: STUDY_DIRECTOR

Janssen Sciences Ireland UC

Locations

Los Angeles, California, United States

Washington D.C., District of Columbia, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Buenos Aires, , Argentina

Ciudad Autonoma de Buenos Aire, , Argentina

Belo Horizonte, , Brazil

Ribeirão Preto, , Brazil

Rio de Janeiro, , Brazil

Montreal, Quebec, Canada

Lyon, , France

Paris, , France

Panama City, , Panama

Rio Piedras, , Puerto Rico

Bucharest, , Romania

Bloemfontein, , South Africa

Boksburg, , South Africa

Cape Town, , South Africa

Dundee, , South Africa

Durban, , South Africa

George, , South Africa

Johannesburg, , South Africa

Newtown, , South Africa

Pretoria, , South Africa

Esplugues de Llobregat, , Spain

Madrid, , Spain

Seville, , Spain

Bangkok, , Thailand

Khon Kaen, , Thailand

Countries

Guatemala; Italy; Portugal; United Kingdom; United States; Argentina; Brazil; Canada; France; Panama; Puerto Rico; Romania; South Africa; Spain; Thailand

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

TMC125-TIDP35-C239

Identifier Type: OTHER

Identifier Source: secondary_id

2009-013126-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CR016408

Identifier Type: -

Identifier Source: org_study_id